Renal cell carcinoma: An update for the practicing urologist

Renal cell carcinoma: An update for the practicing urologist

Systemic therapy for metastatic renal cell carcinoma (mRCC) has evolved drastically, with agents targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) now representing a standard of care. The present paper is to review the current status of relevant clinica...

Full description

Bibliographic Details
Main Authors: Sumanta K. Pal, Paulo Bergerot, Robert A. Figlin
Format: Article
Language:English
Published: Elsevier 2015-01-01
Series:Asian Journal of Urology
Subjects:
Renal cell carcinoma
Sdjuvant therapy
Cytoreductive nephrectomy
Vaccines
Immunotherapy
PD-1
Cabozantinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2214388215000363

Internet

http://www.sciencedirect.com/science/article/pii/S2214388215000363

Similar Items